Dr. Shireen Sirhan is a hematologist, medical oncologist, and Assistant Professor at McGill University, with clinical appointments at the Jewish General Hospital . She is nationally and internationally recognized for her expertise in MPNs , with a strong focus on clinical trials, health system advocacy, and academic leadership. Dr. Sirhan co-established the first dedicated Myeloproliferative Neoplasms clinic in Canada at the Jewish General Hospital, providing specialized multidisciplinary care, advanced diagnostic testing, and access to innovative clinical trials. She is a founding member and current President of the Canadian MPN Group, and serves as Vice-President for Research in MPNs with the Groupe Québécois de recherche en LMC-NMP. She also serves on the Scientific Subcommittee on Artificial Intelligence in Hematology for the American Society of Hematology (ASH) and is a member of multiple Canadian national guideline initiatives for MPNs and mastocytosis. In 2025, Dr. Sirhan led national efforts to secure the exceptional importation of Ropeginterferon alfa-2b (Besremi) in response to a Pegasys shortage, ensuring continued treatment access for patients with MPNs across Canada. She has authored or co-authored several peer-reviewed publications,. In addition to her academic and clinical work, Dr. Sirhan is actively involved in mentorship, national collaboration, and the development of AI-driven strategies in hematologic oncology.

Dr. Shireen Sirhan is a hematologist, medical oncologist, and Assistant Professor at McGill University, with clinical appointments at the Jewish General Hospital . She is nationally and internationally recognized for her expertise in MPNs , with a strong focus on clinical trials, health system advocacy, and academic leadership. Dr. Sirhan co-established the first dedicated Myeloproliferative Neoplasms clinic in Canada at the Jewish General Hospital, providing specialized multidisciplinary care, advanced diagnostic testing, and access to innovative clinical trials. She is a founding member and current President of the Canadian MPN Group, and serves as Vice-President for Research in MPNs with the Groupe Québécois de recherche en LMC-NMP. She also serves on the Scientific Subcommittee on Artificial Intelligence in Hematology for the American Society of Hematology (ASH) and is a member of multiple Canadian national guideline initiatives for MPNs and mastocytosis. In 2025, Dr. Sirhan led national efforts to secure the exceptional importation of Ropeginterferon alfa-2b (Besremi) in response to a Pegasys shortage, ensuring continued treatment access for patients with MPNs across Canada. She has authored or co-authored several peer-reviewed publications,. In addition to her academic and clinical work, Dr. Sirhan is actively involved in mentorship, national collaboration, and the development of AI-driven strategies in hematologic oncology.

Following my graduation from Trinity College - Dublin Ireland in 1993, He completed his general medicine as well as haematology/ oncology training in Dublin, Ireland and Fred Hutch cancer centre in Seattle USA, where he did his training in Bone marrow transplant. In 1999 he joined Sultan Qaboos University and in 2005 he was appointed as head of department of haematology for 10 years. Previously also he held the position of deputy director of Sultan Qaboos university hospital for clinical affairs (clinical director) for 5 years. Research interests include sickle cell disease, chronic leukemia and myeloproliferative disorders with over 140 articles published in international peer reviewed journals including NEJM, haematologica, and blood. He is the founder of Oman hereditary blood disorders association, and chairman of board.